Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.35 |
| ▸ | CLK1 | P49759 | 1/20 | 0.35 |
| ▸ | CLK2 | P49760 | 1/20 | 0.35 |
| ▸ | CLK3 | P49761 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.35 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27108411 | 0.77 | MAOA (0.39) | KDM4EALDH1A1POLBTDP1L3MBTL1 | |
| SCHEMBL21301424 | 0.77 | KDM4E (0.66) | KDM4EALDH1A1POLBTDP1L3MBTL1 | |
| SCHEMBL29528695 | 0.76 | PTGS1 (0.57) | KDM4EPOLBTDP1L3MBTL1NAPRT | |
| SCHEMBL23633192 | 0.75 | ALDH1A1 (0.56) | KDM4EALDH1A1POLBTDP1L3MBTL1 | |
| SCHEMBL15068553 | 0.75 | KDM4E (0.68) | KDM4EALDH1A1POLBTDP1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL9121846 | 0.75 | KDM4E (0.61) | KDM4EALDH1A1POLBTDP1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL27146172 | 0.74 | ALDH1A1 (0.55) | KDM4EALDH1A1POLBTDP1L3MBTL1 | |
| SCHEMBL7573834 | 0.73 | KMT2A (0.47) | ALDH1A1 | |
| SCHEMBL22530986 | 0.72 | KDM4E (0.52) | KDM4EALDH1A1POLBTDP1L3MBTL1 | |
| SCHEMBL29528751 | 0.71 | TGFBR1 (0.41) | KDM4EPOLBTDP1CLK1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1718649-B1 | IMIDAZO 1,2-C PYRIMIDINYLACETIC ACID DERIVATIVES | ACTIMIS PHARMACEUTICALS INC (US) | 2009-06-10 | — | — | EP | claimed |
| US-20090012102-A1 | Imidazo[1,2-C]Pyrimidinylacetic Acid Derivatives | ACTIMIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | US | claimed |
| EP-1718649-A2 | IMIDAZO 1,2-C PYRIMIDINYLACETIC ACID DERIVATIVES | Actimis Pharmaceuticals, Inc., (US) | 2006-11-08 | — | — | EP | claimed |
| WO-2005073234-A2 | IMIDAZO[1,2-C]PYRIMIDINYLACETIC ACID DERIVATIVES | ACTIMIS PHARMACEUTICALS, INC. (US) | 2005-08-11 | — | — | WO | claimed |
| EP-2627178-B1 | QUINAZOLINONE-TYPE COMPOUNDS AS CRTH2 ANTAGONISTS | MERCK SHARP & DOHME (US) | 2018-05-02 | — | — | EP | disclosed |
| US-8927559-B2 | Quinazolinone-type compounds as CRTH2 antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20130210805-A1 | QUINAZOLINONE-TYPE COMPOUNDS AS CRTH2 ANTAGONISTS | MERCK SHARP & DOHME LLC | 2013-08-15 | — | — | US | disclosed |
| US-7750014-B2 | Imidazo[1,2-C]pyrimidinylacetic acid derivatives | ACTIMIS PHARMACEUTICALS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-7750014-B2 | Imidazo[1,2-C]pyrimidinylacetic acid derivatives | ACTIMIS PHARMACEUTICALS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-7750014-B2 | Imidazo[1,2-C]pyrimidinylacetic acid derivatives | ACTIMIS PHARMACEUTICALS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| CN-100584844-C | Imidazole [1,2-C] pyrimidyl acetic acid derivs | ACTIMIS PHARMACEUTICALS INC | 2010-01-27 | — | — | CN | disclosed |
| EP-1718649-B1 | IMIDAZO 1,2-C PYRIMIDINYLACETIC ACID DERIVATIVES | ACTIMIS PHARMACEUTICALS INC (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20090012102-A1 | Imidazo[1,2-C]Pyrimidinylacetic Acid Derivatives | ACTIMIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20090012102-A1 | Imidazo[1,2-C]Pyrimidinylacetic Acid Derivatives | ACTIMIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| CN-1938310-A | Imidazo 1,2-c pyrimidinylacetic acid derivatives | ACTIMIS PHARMACEUTICALS INC (US) | 2007-03-28 | — | — | CN | disclosed |
| EP-1718649-A2 | IMIDAZO 1,2-C PYRIMIDINYLACETIC ACID DERIVATIVES | Actimis Pharmaceuticals, Inc., (US) | 2006-11-08 | — | — | EP | disclosed |
| EP-1718649-A2 | IMIDAZO 1,2-C PYRIMIDINYLACETIC ACID DERIVATIVES | Actimis Pharmaceuticals, Inc., (US) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005073234-A3 | IMIDAZO[1,2-C]PYRIMIDINYLACETIC ACID DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2005-10-06 | — | — | WO | disclosed |
| WO-2005073234-A2 | IMIDAZO[1,2-C]PYRIMIDINYLACETIC ACID DERIVATIVES | ACTIMIS PHARMACEUTICALS, INC. (US) | 2005-08-11 | — | — | WO | disclosed |
| WO-2005073234-A2 | IMIDAZO[1,2-C]PYRIMIDINYLACETIC ACID DERIVATIVES | ACTIMIS PHARMACEUTICALS, INC. (US) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210805-A1 | QUINAZOLINONE-TYPE COMPOUNDS AS CRTH2 ANTAGONISTS | HRH2, NR3C2, HRH1 | KDM4E 4309/4885ALDH1A1 1530/4885POLB 4536/4885 |
| US-20090012102-A1 | Imidazo[1,2-C]Pyrimidinylacetic Acid Derivatives | HRH2, CCR2, HRH1 | KDM4E 4745/4885ALDH1A1 1532/4885POLB 3671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.